|
12/10/2007
|
Oscient Pharmaceuticals Appoints John R. Leone to Board of Directors
|
|
11/20/2007
|
Dyax and MorphoSys Sign License Agreement on Antibody-Related Patents
|
|
10/29/2007
|
Oglemilast, Glenmark's lead molecule for Asthma / COPD receives US FDA nod to initiate further Phase II trials
|
|
10/19/2007
|
Pharming Raises 70 Million Euro Through the Issue of Convertible Bonds Agreement with Paul Capital Healthcare to be Restrucured
|
|
10/11/2007
|
Acorda Therapeutics Files Lawsuit Against Apotex Corp. and Apotex Inc. Relating to Zanaflex Capsules
|
|
10/10/2007
|
Glenmark Receives US FDA Approval for the First Generic Version of Trileptal OrCel Files PMA for OrCel for VLU Indication
|
|
10/1/2007
|
"Masters of Invention" (pdf)
|
|
9/10/2007
|
Glenmark receives US FDA approval for the first generic version of Coreg – Carvedilol
|
|
9/5/2007
|
Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic Antibodies
|
|
9/5/2007
|
Acorda Therapeutics Announces Receipt of ANDA Filing for Zanaflex Capsules™
|
|
9/1/2007
|
Equity Bridges and the Secondary Market for Private Equity
|
|
8/30/2007
|
Pharming Presents Positive Results from European Phase 111 Trial of Rhucin
|
|
8/20/2007
|
Pharming Reports Positive Results in European Placebo-Controlled Trial of Rhucin® In Hereditary Angioedema
|
|
8/14/2007
|
Application for Rotarix® by AVANT's Partner, GlaxoSmithKline, is Accepted for Review by the FDA
|
|
8/2/2007
|
Dyax Corp. Licenses Antibody Phage Display Libraries to Cambridge Antibody Technology
|
|
7/30/2007
|
Orthovita Announces $32.5 Million Equity Offering, $45 Million Debt Facility, and Repurchase of Revenue Interest Obligation
|
|
7/19/2007
|
Dyax Corp. Expands Patent Protection for DX-88 in On-Pump Cardiothoracic Surgery (CTS)
|
|
7/13/2007
|
Pharming Facilities Obtain GMP Status - Important progress in European approval process of Rhucin®
|
|
7/6/2007
|
"Financial Wizards Concoct New Potions" (pdf)
|
|
7/3/2007
|
Glenmark receives US FDA approval for Terbinafine Hydrochloride tablets
|
|
7/1/2007
|
Bank M&A and the Secondary Market for Private Equity
|
|
6/27/2007
|
AVANT's Partner, GlaxoSmithKline, Files Rotarix(R) Application for U.S. Marketing Approval with the FDA
|
|
6/26/2007
|
Austin-Based Medical Carbon Research Institute, LLC. Becomes On-X Life Technologies, Inc.
|
|
6/6/2007
|
Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
|
|
5/22/2007
|
Acorda Therapeutics and FDA Reach Agreement on Special Protocol Assessment for Second Phase 3 Study of Fampridine-SR in Multiple Sclerosis
|
|
5/22/2007
|
Dyax Corp. Announces Expansion of Research Agreement with Trubion Pharmaceuticals, Inc.
|
|
5/16/2007
|
Glenmark receives US FDA approval to market generic Pravastatin Sodium, Naproxen Sodium and Naproxen
|
|
5/2/2007
|
FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day
|
|
5/1/2007
|
Anaphylaxis Treatment Made Easier with New, Enhanced Twinject® Design
|
|
3/28/2007
|
Paul Capital Partners Adds Lara S. Sullivan, MD to Healthcare Team
|
|
3/26/2007
|
Paul Capital Healthcare Amends Agreements with SkyePharma PLC
|
|
3/20/2007
|
Paul Capital Partners Appoints John R. Leone Partner
|
|
2/2/2007
|
Acorda Therapeutics Receives Additional $5 Million from Paul Capital Healthcare
|
|
1/16/2007
|
Pharming Receives European Orphan Drug Designation
|
|
1/8/2007
|
Acorda Therapeutics Announces Completion of Zanaflex Capsules™ Sales Force Expansion
|